1)Wu L, Evans T, Saravia M et al:Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Vogt-Koyanagi-Harada syndrome. Jpn J Ophthalmol 53:57-60, 2009
2)Vinores SA, Chan CC, Vinores MA et al:Increased vascuar endothelial growth factor(VEGF)and transforming growth factor beta(TGFbeta)in experimental autoimmune uveoretinitis:upregulation of VEGF wiyhout neovascularization. J Neuroimmunol 89:43-50, 1998
3)Read RW, Rechodouni A, Butani N et al:Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol 131:599-606, 2001
4)Lertsumitkul S, Whitcup SM, Nussenblatt RB et al:Subretinal fibrosis and choroidal neovascularization in Vogt-Koyanagi-Harada syndrome. Graefes Arch Clin Exp Ophthalmol 237:1039-1045, 1999
5)Moorthy RS, Chog LP, Smith RE et al:Subretinal neovascular membranes in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 116:164-170, 1993
6)Inomata H, Minei M, Taniguchi Y et al:Choroidal neovascularization in long-standing case of Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 27:9-26, 1983
7)Park HS, Nam KY, Kim JY:Intravitreal bevacizumab injection for persistent serous retinal detachment associated with Vogt-Koyanagi-Harada disease. Graefes Arch Clin Exp Ophthalmol 249:133-136, 2011